PHARMALAUNCHER

Before founding Pharma Launcher, Dr. Tsaioun was Chief Scientific Officer at Cyprotex, the world's largest contract research organization specializing in ADME Tox. Cyprotex is a publicly traded, UK-based company with laboratories in the US and UK.. Dr. Tsaioun joined Cyprotex subsequent to Cyprotex's 2010 acquisition of Apredica, where she was a co-founder and President. At Cyprotex, Dr. Tsaioun managed scientific strategy and strategic alliances, particularly focusing on the ADME Tox technologies developed at Apredica, and those which Apredica acquired from Cellumen. Apredica opened for business in 2006. In four years Dr. Tsaioun grew Apredica from 1.5 to 12 FTEs. Apredica initially focused on preclinical ADME contract research, then expanded to become an early leader in the in vitro toxicology market... Dr. Tsaioun is a widely recognized expert in preclinical drug-discovery research. Her book, ADMET for Medicinal Chemists, was published in 2011 by Wiley & Sons. Dr. Tsaioun serves on..

Also known as: PharmaLauncher LLC

Primary location: Orleans United States